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ACCORD Action to Control Cardiovascular Risk in
Diabetes
ADVANCE Action in Diabetes and Vascular Disease:
Preterax and Diamicron Modified Release
Controlled Evaluation
NNT Number needed to treat
UKPDS UK Prospective Diabetes Study
VADT Veterans Affairs Diabetes Trial
To the Editor: In their Editorial, Yudkin, Richter and Gale
argue that ‘Hyperglycaemia is a substantially weaker risk
factor for CVD than cholesterol or blood pressure, and
glucose-lowering interventions are correspondingly less
effective’ [1]. They come to this conclusion on the basis of
number needed to treat (NNT) derived from epidemiolog-
ical studies, the UK Prospective Diabetes Study [2]a n d
three recent megatrials (Action to Control Cardiovascular
Risk in Diabetes [ACCORD] [3], Action in Diabetes and
Vascular Disease: Preterax and Diamicron Modified Re-
lease Controlled Evaluation [ADVANCE] [4] and Veterans
Affairs Diabetes Trial [VADT] [5]), which were subsequent-
ly meta-analysed. Of course, the results of any meta-analysis
are dependent on the validity of the individual trials
analysed. The external validity of ACCORD and VADT is
severely compromised with the recent decision of the
European Medicines Agency to retract the market author-
isation of rosiglitazone. In VADT, all patients in the
intensively treated group were started on rosiglitazone by
trial design. In ACCORD, 91.2% of patients were on
rosiglitazone in the intensively treated group. It seems
impossible to draw any conclusion on possible cardiovas-
cular benefits of glucose lowering if such glucose lowering
was attained using a drug which has now been concluded to
increase the risk of myocardial infarction by its very nature.
So we are left with UKPDS and ADVANCE as the relevant
studies. The key differentiators between these two studies
are duration of disease at enrolment and the treatment
targets in the intensively and conventionally treated groups.
In UKPDS, patients were randomised soon after the
diagnosis of type 2 diabetes was made, and ADVANCE
enrolled patients with a diabetes duration of 8 years. Using
the UKPDS follow-up data [6], Yudkin et al. calculated the
NNT for 10 years to prevent one myocardial infarction or
stroke to be 29.4 [1]. This number relates to the sulfonyl-
urea–insulin group. In the metformin group, the
corresponding NNT is 14. Moreover, the 10 year NNT to
prevent one death was 29 in the sulfonylurea–insulin and 14
in the metformin group. I think most diabetologists would
agree that patients with newly diagnosed diabetes are
entitled to treatment aiming to achieve an HbA1c value of
<7.0% for at least 10 years. There is no reason to believe
that the UKPDS results would have been different if the trial
had been of longer duration, so it seems reasonable to keep
this as the HbA1c target. After the first 10 years of diabetes,
ADVANCE becomes a relevant study. This study showed
only minimal beneficial effects of intensive treatment of
glucose as compared with conventional treatment, but it
should be noted that mean HbA1c in the conventionally
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There is no trial evidence to indicate that HbA1c levels above
this are safe. Therefore, treatment guidelines will probably
continue to advise a target HbA1c of 7.0% for people with
diabetes, with the possibility of a slightly higher target of
7.3% after a diabetes duration of 8–10 years. Of course,
considerations relating to hypoglycaemia, weight gain,
diminished life-expectancy or adherence may well justify
higher targets in selected individuals.
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